The Challenge with Canine Cancer
Cancer is the leading cause of death in dogs. While their lifetime risk is similar to humans (between 1:2 and 1:4), their annual cancer incidence is up to ten times higher because of their shorter lifespans.1-5 Like in people, both genetic and environmental factors drive cancer incidence in dogs. Some purebred dogs may carry a higher number of germline (inherited) mutations that predispose them to cancer. Furthermore, because dogs and humans share the same environment, dogs are exposed to the same carcinogens as their owners.6,7 Additionally, the burden of cancer in dogs increases with age: up to 50% of dogs >10 years of age will develop cancer during the remainder of their lives.3,8,9
Cancer care is an essential part of pet health care.10 Unfortunately, most patients are presented for evaluation once clinical signs develop, by which time the cancer is often advanced, microscopic or macroscopic spread has already occurred, and a cure is no longer achievable.10-14 Thus, cancer in dogs currently carries a significant burden of morbidity and mortality.3,15,16
The conventional path to achieving a cancer diagnosis in dogs varies based on the patient characteristics, tumor type, and tumor location.17 Traditional diagnostics include tissue biopsy, exploratory surgery, and fine needle aspiration (FNA) cytology. These diagnostic tests are associated with variable levels of risk dependent upon the site of the suspected mass and the characteristics of the procedure; such risks include infection, internal bleeding, fracture after bone biopsy, non-diagnostic results, and in the worst cases, death.17-28 FNA is less invasive and lower risk compared to biopsy; however, inconclusive results or misdiagnoses are common with FNA.29,30 Also, not all tumors are easily accessible to sampling by FNA.
By leveraging advances in genomic technology and oncology, PetDx® has created the first-of-its kind test for the detection, characterization, and management of canine cancer based on a simple blood draw:
OncoK9® – The Liquid Biopsy Test for Dogs™
What is Liquid Biopsy?
Liquid biopsy typically refers to the sampling and analysis of cancer-related analytes from blood. The unique, non-invasive nature of liquid biopsy allows it to be deployed in multiple clinical use cases across the full spectrum of cancer care in dogs, including screening, aid in diagnosis, targeted treatment selection, treatment response monitoring, minimal residual disease detection, and recurrence monitoring.31 This method has unique advantages, especially in cancer (or cancer-suspected) cases where obtaining a tissue sample for traditional histological analysis may be particularly risky or difficult.
How OncoK9 Works
Cancer is a disease of the genome and develops as the result of the successive accumulation of genomic alterations (DNA mutations) in body cells over time; these are known as somatic (or acquired) mutations. Cancer occurs when one or more of these alterations confer an uncontrolled growth advantage to a population of cells.32
When cells die, DNA within the nucleus is broken down into small fragments which get released into the bloodstream as ‘cell-free’ DNA (cfDNA). Both normal and cancer cells release cfDNA, but the fragments arising from the cancer cells can be distinguished from those originating in normal cells by examining their DNA sequence.33 The OncoK9 liquid biopsy test interrogates millions of cfDNA fragments in each blood sample, using next-generation sequencing (NGS) technology and bioinformatics algorithms to non-invasively detect alterations in the DNA that indicate the presence of cancer.
When to Use OncoK9
OncoK9 is a multi-cancer early detection (MCED) test for the detection and characterization of cancer-associated genomic alterations in DNA isolated from canine whole blood samples, using next-generation sequencing (NGS) technology. OncoK9 is intended for use in dogs who are at higher risk of cancer. It is recommended as an annual screening test for all dogs starting at 8 years of age, and potentially at younger ages for dogs belonging to breeds that are highly predisposed to cancer. It is also recommended as an aid-in-diagnosis for dogs in which cancer is suspected based on clinical signs or other clinical findings. As with any laboratory test, OncoK9 results should be interpreted by a veterinarian in the context of each patient’s medical history and clinical presentation. The test is available by prescription only.
Interpretation of Results
OncoK9 alerts the veterinarian to genomic alterations associated with the presence of cancer by reporting one of three results:
CANCER SIGNAL NOT DETECTED
A Cancer Signal Not Detected result indicates that no cancer-associated genomic alterations were detected in the DNA from the patient’s blood sample. This significantly reduces but does not eliminate the probability that cancer is present. If cancer is clinically suspected, a full diagnostic evaluation should be performed. Consider re-testing if cancer remains high on the differential diagnosis list, as advancing disease generally provides a higher cancer signal.
CANCER SIGNAL DETECTED
A Cancer Signal Detected result indicates that cancer-associated genomic alterations were detected in the DNA from the patient’s blood sample. This significantly increases the probability that cancer is present but does not establish a definitive diagnosis of cancer. A full clinical evaluation must be performed to establish a definitive diagnosis in this patient. This result should not be used as the sole basis for making important decisions such as treatment or euthanasia.
A Not Reportable result indicates that the sample sent to PetDx did not meet internal quality criteria for a reportable result, and submission of a new sample is typically advised. The report will provide instructions about submitting a new sample.
As with any laboratory test result, close consultation between the veterinarian and dog owner is necessary to ensure that test results are interpreted for each patient in the context of their unique clinical presentation.
By leveraging breakthrough technology from the human oncology arena, PetDx has created OncoK9, a non-invasive liquid biopsy test that has the potential to revolutionize the detection, characterization, and management of cancer in canine patients.
1. Pang LY, Argyle DJ. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochim Biophys Acta. (2009) 1792:380– 91. doi: 10.1016/j.bbadis.2009.02.010
2. Pang LY, Argyle DJ. Veterinary oncology: biology, big data and precision medicine. Vet J. (2016) 213:38–45. doi: 10.1016/j.tvjl.2016.03.009
3. Fleming JM, Creevy KE, Promislow DEL. Mortality in North American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death. J Vet Intern Med. (2011) 25:187–98.doi: 10.1111/j.1939-1676.2011.0695.x
4. LeBlanc AK, Mazcko CN. Improving human cancer therapy through the evaluation of pet dogs. Nat Rev Cancer.(2020) 20:727–42.doi: 10.1038/s41568-020-0297-3
5. Baioni E, Scanziani E, Vincenti MC, Leschiera M, Bozzetta E, Pezzolato M, et al. Estimating canine cancer incidence: findings from a population-based tumour registry in northwestern Italy. BMC Vet Res. (2017) 13:203. doi: 10.1186/s12917-017- 1126-0
6. Dobson JM. Breed-predispositions to cancer in pedigree dogs. Isrn Vet Sci. (2013) 2013:1–23. doi: 10.1155/2013/941275
7. Pinello KC, Niza-Ribeiro J, Fonseca L, Matos AJ. Incidence, characteristics and geographical distributions of canine and human non-Hodgkin’s lymphoma in the Porto region (North West Portugal).Vet J. (2019) 245:70–6.doi: 10.1016/j. tvjl.2019.01.003
8. Schiffman JD, Breen M. Comparative oncology: what dogs and other species can teach us about humans with cancer. Philos Trans R Soc B Biol Sci. (2015) 370:20140231. doi: 10.1098/rstb.2014.0231
9. Klingemann H. Immunotherapy for dogs: running behind humans. Front Immunol. (2018) 9:133. doi: 10.3389/fimmu.2018.00133
10. Biller B, Berg J, Garrett L, Ruslander D, Wearing R, Abbott B, et al. 2016AAHA oncology guidelines for dogs and cats. J Am Anim Hosp Assoc.(2016)52:181–204. doi: 10.5326/jaaha-ms-6570
11. Williams LE, Packer RA. Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987-2001). J Am Vet Med Assoc. (2003) 222:1234–6. doi: 10.2460/javma.2003.222.1234
12. Polton GA, Brearley MJ. Clinical stage, therapy, and prognosis in canine anal sac gland carcinoma. J Vet Intern Med. (2007) 21:274–80.doi: 10.1111/j.1939-1676.2007.tb02960.x
13. Flory AB, Rassnick KM, Stokol T, Scrivani PV, Erb HN. Stage migration in dogs with lymphoma. J Vet Intern Med. (2007) 21:1041–7.doi: 10.1111/j.1939-1676.2007.tb03062.x
14. Wendelburg KM, Price LL, Burgess KE, Lyons JA, Lew FH, Berg J. Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001-2012). J Am Vet Med Assoc. (2015) 247:393–403. doi: 10.2460/javma.247.4.393
15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020.CA Cancer J Clin. (2020) 70:7–30. doi: 10.3322/caac.21590
16. Cancer Statistics. National Cancer Institute. NCI (2021) Available online at: https:// www.cancer.gov/about-cancer/understanding/statistics (accessed June 14, 2021).
17. Ehrhart N, Culp W. Chapter 1: Principles of surgical oncology. In: Kudnig S, Seguin B, editors. Veterinary Surgical Oncology. Wiley Blackwell (2012). Retrieved from: www. mazon.com.
18. Simon MA. Biopsy of musculoskeletal tumors. J Bone Jt Surg. 1982;64(8):1253–7.
19. Guilford W. Gastrointestinal endoscopy. In: Guilford W, Center S, Strombeck D, editors. Strombeck’s Small Animal Gastroenterology. 3rd ed. Philadelphia, PA: Saunders. (1995). p. 114–29.
20. Willard M, Schuz K, Hayashi K. Chapter 14: Principles of minimally invasive surgery and imaging of the surgical patient. In: Fossum T, Duprey LP, editors. Small Animal Surgery. 5th ed. Elsevier. Retrieved from: www.Amazon.com
21. Pratschke KM, Ryan J, McAlinden A, McLauchlan G. Pancreatic surgical biopsy in 24 dogs and 19 cats: postoperative complications and clinical relevance of histological findings. J Small Anim Pract. (2015) 56:60–6.doi: 10.1111/jsap.12262
22. de Rycke LMJH, Bree HJJ van, Simoens PJM. Ultrasound-guided tissue-core biopsy of liver, spleen and kidney in normal dogs. Vet Radiol Ultrasound. (1999) 40:294–9. doi: 10.1111/j.1740-8261.1999.tb00364.x
23. Bagley RS. Spinal neoplasms in small animals. Vet Clin North Am Small Animal Pract. (2010) 40:915–27. doi: 10.1016/j.cvsm.2010.05.010
24. Shales CJ, Warren J, Anderson DM, Baines SJ, White RAS. Complications following full-thickness small intestinal biopsy in 66dogs: a retrospective study. J Small Anim Pract. (2005) 46:317–21. doi: 10.1111/j.1748-5827.2005.tb00326.x
25. Weisse C, Soares N, Beal MW, Steffey MA, Drobatz KJ, Henry CJ. Survival times in dogs with right atrial hemangiosarcoma treated by means of surgical resection with or without adjuvant chemotherapy: 23 cases (1986-2000). J Am Vet Med Assoc.(2005) 226:575–9. doi: 10.2460/javma.2005.226.575
26. Mamelak AN, Owen TJ, Bruyette D. Transsphenoidal surgery using a high definition video telescope for pituitary adenomas in dogs with pituitary dependent hypercortisolism: methods and results. Vet Surg. (2014) 43:369–79. doi: 10.1111/j.1532- 950x.2014.12146.x
27. Rijn SJ van, Galac S, Tryfonidou MA, Hesselink JW, Penning LC, Kooistra HS, et al. The influence of pituitary size on outcome after transsphenoidal hypophysectomy in a large cohort of dogs with pituitary-dependent hypercortisolism. J Vet Intern Med. (2016) 30:989–95.doi: 10.1111/jvim.14367
28. Harris BJ, Lourenço BN, Dobson JM, Herrtage ME. Diagnostic accuracy of three biopsy techniques in 117 dogs with intra-nasal neoplasia. J Small Anim Pract. (2014) 55:219–24. doi: 10.1111/jsap.12187
29. Sharkey LC, Dial SM, Matz ME. Maximizing the diagnostic value of cytology in small animal practice. Vet Clin North Am Small Animal Pract. (2007)37:351–72. doi: 10.1016/j.cvsm.2006.11.004
30. DeBerry JD, Norris CR, Samii VF, Griffey SM, Almy FS. Correlation between fine-needle aspiration cytopathology and histopathology of the lung in dogs and cats. J Am Anim Hosp Assoc. (2014) 38:327–36. doi: 10.5326/0380327
31. Chibuk J, Flory A, Kruglyak KM, Leibman N, Nahama A, Dharajiya N, et al. Horizons in Veterinary Precision Oncology: Fundamentals of Cancer Genomics and Applications of Liquid Biopsy for the Detection, Characterization, and Management of Cancer in Dogs. Frontiers Vet Sci. 2021;8:664718.
32. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Kinzler KW. Cancer genome landscapes. Science.(2013) 339:1546–58. doi: 10.1126/science.1235122
33. Kruglyak KM, Chibuk J, McLennan L, Nakashe P, Hernandez GE, Motalli-Pepio R, et al. Blood-Based Liquid Biopsy for Comprehensive Cancer Genomic Profiling Using Next-Generation Sequencing: An Emerging Paradigm for Non-invasive Cancer Detection and Management in Dogs. Frontiers Vet Sci. 2021;8:704835.